Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The chronological changes of transcriptomic profiles of hepatic macrophages after partial portal vein ligation

ABSTRACT: The chronological changes of transcriptomic profiles of hepatic macrophages after partial portal vein ligation

PROVIDER: PRJNA482244 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The chronological changes of transcriptomic profiles of hepatic macrophages after partial portal vein ligation

Project description:We compared transcriptomic profiles of hepatic macrophages between sham operated rats, rats 3 days and 10 days after partial portal vein ligation (PPVL) surgery (n=3). The number of genes with a significant change was most numerous in Sham vs 3 days, followed by Sham vs 10 days and 3 days vs 10 days.

2019-01-01 | GSE117467 | GEO

Transcription profiling of superior mesenteric arteries from rats that have had portal vein ligation or a sham procedure for different lengths of time

Project description:Twenty-four male Sprague-Dawley rats were used for this experiment, a partial portal vein ligadure (PVL) was carried out in 12 rats, the other 12 rats were sham-operated. Superior mesenteric artery (SMA) samples were sequentially obtained from 2 rats from the PVL and sham groups at 1, 6, and 24 hours, and 3, 5 and 14 days after portal vein ligation or sham procedure. Each PVL sample was paired with its corresponding sham sample using a dye swap experiment design (technical replicates) resulting in 12 arrays (6 time points x 2 dye swap).

2008-05-09 | E-MEXP-1107 | biostudies-arrayexpress

Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)

Project description:Surgical resection has offered the best option for prolonged survival in patients with colorectal liver metastases. Limiting factor for major liver resections is the size of the future liver remnant (FLR). In case of normal liver function, 30% of the total liver volume is considered to be sufficient to maintain adequate liver function after resection. In an attempt to further increase "resectability" criteria for patients with too small FLR surgical and interventional maneuvers such as portal vein embolization and portal vein ligation in two-stage hepatectomies have been implemented, but they need an interval of 4-8 weeks to achieve sufficient hypertrophy. In order to obtain adequate but rapid parenchymal hypertrophy a new surgical two-step technique, ALPPS, was introduced for oncological patients requiring extended hepatic resection with limited functional reserve. Both procedures can be performed with acceptable morbidity and mortality. The investigators conclude that it is time to perform a randomized study comparing the two surgical approaches in regard to oncological outcome.

| 2214133 | ecrin-mdr-crc

Application research of recanalization of the umbilical vein in portal vein embolization in radical hepatectomy of colorectal liver metastasis

Project description:Interventions: One group:portal vein embolization approach-recanalization of the umbilical vein Primary outcome(s): Portal vein catheter success rate Study Design: historical control

| 2668806 | ecrin-mdr-crc

Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

Project description:The hypothesis is that liver venous deprivation (LVD) could strongly improve hypertrophy of the future remnant liver (FRL) at 3 weeks, as compared to portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.

| 2297214 | ecrin-mdr-crc

CNV analysis of hepatocellular carcinoma with portal vein tumor thrombosis

Project description:Portal vein tumor thrombosis is a strong poor indication of HCC. Characterizing the molecular alterations of these metastatic HCCs is important for understanding the molecular mechanisms during HCC progression and metastasis. Previous genomic studies mainly focus on single molecular layer, such as gene expressions or exonic mutations. In this study, we systematically examined the copy number variation (CNV), DNA methylation, miRNA and transcriptome of matched adjacent normal tissues, primary tumors and PVTTs from 19 HCC patients. Based on the integrative multi-omics profiles, we established the molecular landscape of the metastatic HCCs and identified a set of the recurrent genomic alterations and candidate driver genes.

2017-02-17 | GSE77275 | GEO

The gene expression profiling array of mRNAs and LncRNA between portal vein tumor thrombus tissues and paired tumor tissues in hapatocellular carcinoma

Project description:Investigation of whole genome gene expression level changes of mRNAs and LncRNAs in portal vein tumor thrombus tissues and paired tumor tissues in hapatocellular carcinoma. The different expression genes were further analyzed.

2013-01-19 | GSE43630 | GEO

Expression data from patients of idiopathic portal hypertension

Project description:Idiopathic portal hypertension (IPH) is characterized by portal hypertension due to obstruction or stenosis of the intrahepatic peripheral portal branches. Researchers have suggested that IPH may be attributed to intrahepatic peripheral portal vein thrombosis, splenic factors, abnormal autoimmunity, and related factors, however, the etiology of IPH remains unclear. We used microarrays to identify the functions of genes expressed in blood samples from patients with IPH.

2015-06-06 | GSE69601 | GEO

The molecular landscape of hepatocellular carcinoma with portal vein tumor thrombosis

Project description:The molecular landscape of hepatocellular carcinoma with portal vein tumor thrombosis

| PRJNA309945 | ENA

Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

Project description:RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.

| 2007016 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data